Medical device manufacturers seeking to market products in Great Britain and Northern Ireland must now register with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), according to updated UK government guidance. The requirement reflects post-Brexit regulatory changes that separated the British approval pathway from the European Union’s framework, creating distinct registration obligations for manufacturers across the two markets.
Key takeaways
- Medical device manufacturers must register separately with the MHRA for market access in Great Britain and Northern Ireland
- Registration requirements differ from the previous EU-aligned system and apply to both new and existing products
- The MHRA process is now a distinct regulatory pathway separate from EU CE marking procedures
Manufacturers previously relying on single EU approval pathways must now complete separate registration processes for the UK market, a significant operational change for the medical device industry across Europe. The MHRA’s official guidance outlines specific requirements for device classification, manufacturer documentation, and submission procedures.
Regulatory landscape shift after Brexit
Prior to the UK’s departure from the European Union, medical devices approved through the EU’s conformity assessment procedures received automatic access to the British market. The MHRA now requires all manufacturers to complete independent registration for Great Britain, with separate provisions for Northern Ireland, which maintains limited alignment with EU procedures under the Northern Ireland Protocol.
This regulatory divergence creates operational complexity for multinational manufacturers. Companies must now maintain dual compliance systems—one for the EU market using the CE marking procedure, and a separate registration pathway for the UK market administered by the MHRA. The distinction has implications for device development timelines, quality assurance protocols, and market entry strategies.
UK Medical Device Market Access: Pre- and Post-Brexit Pathways
Regulatory systems comparison, showing separation of UK and EU approval routes
Source: UK MHRA Regulatory Guidance | Georgian Medical Journal News
Medical device manufacturers must now register separately with the MHRA for market access in Great Britain and Northern Ireland, reflecting the UK’s independent regulatory pathway established after Brexit.
— UK Medicines and Healthcare products Regulatory Agency (MHRA)
Registration requirements and manufacturer responsibilities
The MHRA’s published guidance specifies that manufacturers must provide comprehensive documentation including device classification, technical specifications, quality management systems, and clinical evidence. The registration process applies to manufacturers placing devices on the market in both Great Britain and Northern Ireland, with different procedural requirements for each region.
Device classification under the MHRA system follows established risk categories—Class I (lowest risk) through Class III (highest risk)—with corresponding regulatory requirements. Quality and safety standards for device manufacturing, testing, and post-market surveillance must be documented and maintained throughout the product lifecycle. Manufacturers must also designate a UK or Northern Irish responsible person to oversee compliance.
Implications for global medical device industry
The new registration requirements have broader implications for the global medical device supply chain. Manufacturers based in the European Union, United States, and other jurisdictions seeking to enter the British market must now budget additional regulatory resources and timelines beyond their existing EU or international submissions. Clinical updates and device modifications require separate MHRA notification, extending product development cycles for multinational companies.
Healthcare institutions and purchasing organizations in Great Britain and Northern Ireland must ensure their procurement processes account for MHRA registration status. The regulatory divergence between the UK and EU markets may also influence innovation investment patterns, with some manufacturers prioritizing larger markets while others develop region-specific product variants.
What this means
Frequently asked questions
Do manufacturers need separate registration for Great Britain and Northern Ireland?
Yes, according to MHRA guidance, manufacturers must complete registration processes for each market. Northern Ireland has limited alignment with EU procedures under the Northern Ireland Protocol, requiring separate assessment of regulatory requirements before submission.
Can CE marking from the EU be used for UK market access?
No. The MHRA’s post-Brexit system operates independently from the EU’s CE marking procedure. Manufacturers must complete separate MHRA registration even if their device carries CE marking for the European market.
How long does MHRA registration typically take?
Timeline depends on device classification and complexity. The MHRA guidance does not specify fixed approval timelines, as processing duration varies based on documentation completeness and regulatory questions. Manufacturers should contact the MHRA directly for estimated timelines specific to their device category.
As the UK medical device regulatory system matures and establishes operational consistency, manufacturers will develop clearer pathways for market entry. Healthcare systems across Great Britain and Northern Ireland should engage proactively with manufacturers and regulatory authorities to ensure uninterrupted access to critical medical technologies while maintaining appropriate safety oversight.
Source: Register medical devices to place on the market — UK Medicines and Healthcare products Regulatory Agency (MHRA)
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
